Janux Therapeutics Inc (JANX) Price & Analysis

Compare

713 Followers

JANX Stock Chart & Stats

$13.97

-$2.71(-4.69%)

At close: Jan 08 4:00 PM EST

$13.97

-$2.71(-4.69%)

Day’s Range― - ―

52-Week Range$12.12 - $35.34

Previous CloseN/A

Volume1.13M

Average Volume (3M)1.26M

Market Cap

$849.82M

Enterprise Value$831.46M

Total Cash (Recent Filing)$966.57M

Total Debt (Recent Filing)$41.88M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

May 12, 2026

EPS Estimate

-0.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding60,831,657

10 Day Avg. Volume807,039

30 Day Avg. Volume1,260,802

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)0.89

Price to Sales (P/S)85.51

P/FCF Ratio-10.27

Enterprise Value/Market Cap0.98

Enterprise Value/Revenue46.50

Enterprise Value/Gross Profit98.53

Enterprise Value/Ebitda-6.20

Forecast

1Y Price Target

$54.00

Price Target Upside286.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-2.66

Revenue Forecast (FY)$8.68M

Bulls Say, Bears Say

Bulls Say

Autoimmune Pipeline DifferentiationAdvancement of a bispecific autoimmune candidate using a masked immune-modulating platform, with first-in-human dosing underway, could differentiate the company by offering off-the-shelf dosing, reduced toxicity, and deeper B-cell depletion than many current options.

Collaboration ValidationAn exclusive collaboration with a major pharmaceutical company validates the tumor-activated platform and signals external confidence that could increase partnership and licensing value.

Lead Asset Clinical EfficacyEarly clinical results for the lead T cell engager showed strong prostate cancer responses and favorable progression outcomes that compare competitively with existing therapy, supporting potential broader clinical use.

Bears Say

Competitive PressureCompeting T-cell engager programs reporting strong early responses, together with outcomes that match an approved therapy, increase commercial competition and may limit the company's ability to clearly differentiate its lead asset.

Financial RiskA reported net loss highlights ongoing development costs and may increase the need for additional funding, which could pressure the balance sheet and lead to dilution if capital is required.

Safety ConcernsA fatal cardiotoxicity event linked to the program raises safety concerns that could prompt intensified cardiac monitoring, slower enrollment, and heightened regulatory scrutiny.

Janux Therapeutics Inc News

Janux Therapeutics price target lowered to $80 from $100 at Truist

Truist lowered the firm’s price target on Janux Therapeutics (JANX) to $80 from $100 and keeps a Buy...

4d ago

JANX

Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on Janux Therapeutics (JANX) to $100 from $150 and keeps an...

8d ago

JANX

Janux Therapeutics price target lowered to $68 from $72 at Guggenheim

Guggenheim lowered the firm’s price target on Janux Therapeutics (JANX) to $68 from $72 and keeps a Buy...

8d ago

JANX

Janux Therapeutics reports Q4 EPS (51c), consensus (64c)

“The past year marked a period of significant execution and progress for Janux as we continued to translate...

8d ago

JANX

Janux Therapeutics doses first patient in JANX011 trial

Janux Therapeutics (JANX) announced that the first participant has been dosed in a Phase 1 clinical study of...

18d ago

JANX

Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Janux Therapeutics Inc today and set a price...

5d ago

JANX

Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating

Analyst Oliver McCammon from LifeSci Capital maintained a Buy rating on Janux Therapeutics Inc and keeping the price...

8d ago

JANX

Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform

William Blair analyst Matt Phipps has maintained their bullish stance on JANX stock, giving a Buy rating yesterday....

8d ago

JANX

Janux Therapeutics CMO Zachariah McIver to depart, William Go to succeed

Janux Therapeutics (JANX) announced that William Go has been appointed chief medical officer, effective January 26. Go succeeds...

1M ago

JANX

Janux Therapeutics Inks Global Oncology Collaboration With BMS

The latest update is out from Janux Therapeutics Inc ( ($JANX) ). On January 22, 2026, Janux Therapeutics...

1M ago

JANX

Janux Therapeutics: Bristol Myers Collaboration Validates Tumor-Activated Platform and Enhances Risk–Reward Profile

William Blair analyst Matt Phipps has maintained their bullish stance on JANX stock, giving a Buy rating on...

1M ago

JANX

Janux Therapeutics enters exclusive license agreement with Bristol Myers

Janux Therapeutics (JANX) announced a collaboration and exclusive worldwide license agreement with Bristol Myers (BMY). Under the terms...

1M ago

BMY

JANX

Janux Therapeutics downgraded to Hold from Buy at Clear Street

Clear Street downgraded Janux Therapeutics (JANX) to Hold from Buy with a price target of $12, down from...

2M ago

JANX

Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler

Piper Sandler analyst Kelsey Goodwin lowered the firm’s price target on Janux Therapeutics (JANX) to $30 from $42...

2M ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $849.82M.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 66 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on Feb 26, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.115.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.59.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 60,831,657 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went down -1.377%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Janux Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-11.48%

Trailing 12-Months

Asset Growth

-5.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics Inc (JANX) Earnings & Revenues

Historic Earnings Reports

JANX Stock 12 Month Forecast

Average Price Target

$54.00

▲(286.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","56":"$56","101":"$101","33.5":"$33.5","78.5":"$78.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,33.5,56,78.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.42,20.08,26.740000000000002,33.4,40.06,46.72,53.38,60.040000000000006,66.7,73.36,80.02,86.68,93.34,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.42,16.54153846153846,19.663076923076922,22.784615384615385,25.906153846153845,29.027692307692305,32.14923076923077,35.27076923076923,38.39230769230769,41.51384615384615,44.635384615384616,47.75692307692308,50.878461538461536,{"y":54,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.42,13.31076923076923,13.201538461538462,13.092307692307692,12.983076923076924,12.873846153846154,12.764615384615384,12.655384615384616,12.546153846153846,12.436923076923076,12.327692307692308,12.218461538461538,12.10923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 71, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 73, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >